Business Wire

Santen and IAPB Taking Action to Implement the First Ever UN General Assembly Resolution Recognizing the Link Between Eye Health and Sustainable Development

Share

Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services.

Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We take the adoption of this resolution as an opportunity to further enhance our policy and advocacy activities with the IAPB.

“The eye health sector has believed for a long time that quality eye care is critical to the world achieving the Sustainable Development Goals” said Peter Holland, CEO of IAPB. “IAPB and its members are committed to supporting governments to implement this resolution and ensure that no one is left behind”.

To support the implementation of this resolution, Santen and the IAPB will work together on a number of initiatives as part of their ongoing strategic partnership, including:

  • Partnership with national governments and supranational stakeholders to establish an effective monitoring system and encourage the inclusion of eye health in voluntary national reporting on the Sustainable Development Goals (SDGs).
  • Coordination of an advocacy and public affairs strategy to lobby for the inclusion of two eye health targets in the next review of the SDGs by the UN Inter-Agency Expert Group in 2025.

Today, 1.1 billion people are living with preventable sight loss due to a lack of access to basic eye care services. With appropriate allocation of resources and investment for the early detection and treatment of eye conditions, including disease awareness campaigns and regular eye tests, sight can be protected.1 Vision loss can have a significant detrimental impact on quality of life (QOL), including depression, discomfort and social isolation. Improving access to eye care services therefore, has the potential to improve the QOL for millions of people.2 Additionally, sight loss is calculated to cost the global economy $411bn in productivity each year, showing it has tremendous economic consequences3. Eye health is directly linked to more than half of the sustainable development goals (SDGs), including eliminating poverty and hunger, improving education, and gender equality4. Therefore, a “whole of government approach” to eye care and strengthened collaboration between stakeholders is necessary to ensure the people living with preventable sight loss receive access to support and treatment.

“The adoption of UN resolution on eye health represents a major leap towards the realization of our WORLD VISION (Happiness with Vision)” said Shigeo Taniuchi, President & CEO of Santen, “There is ample evidence that eye health is a global development issue. About 90% of preventable vision loss occurs in low and middle income countries, of which 55% affects women and girls. People, in general, receive 80% of information visually and eye disease tend to be chronic, affecting patients’ quality of life. As a specialized company dedicated to ophthalmology, we are committed to promoting international efforts on eye health and contributing to the realization of the SDGs. Supporting the implementation of this resolution is a crucial step towards facilitating access to eye care services and reducing the loss of social and economic opportunities for people around the world due to eye conditions”.

References:

  1. International Agency for the Prevention of Blindness (IAPB). Vision Atlas. Available here: https://www.iapb.org/learn/vision-atlas
  2. Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
  3. Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
  4. Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.
Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.
With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (www.santen.com).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate Communications Group
Santen Pharmaceutical Co., Ltd.
Takahiro Hidaka
E-mail: communication@santen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dubai Brings Together Sport Stars and Legends, Leaders and Decision-Makers on the Largest Global Platform to Shape the Future of Sports: the World Sports Summit18.12.2025 15:40:00 EET | Press release

The Dubai Sports Council has announced the launch of the World Sports Summit (WSS), which will take place under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence and Chairman of the Executive Council of Dubai. The event is set to be held from December 29-30, 2025 at Madinat Jumeirah in Dubai, under the theme ‘Uniting the World Through Sports’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218607571/en/ Dubai Brings Together Sport Stars and Legends, Leaders and Decision-Makers on the Largest Global Platform to Shape the Future of Sports: the World Sports Summit (Photo: AETOSWire) The Summit will be the largest global gathering of its kind, bringing together a distinguished group of top sports decision-makers, experts, global stars, representatives of international sports federations and organisations, investors and innovators

Regula Wins High Customer Marks and Strong Momentum in G2’s Winter 2026 Grid Reports for Identity Verification18.12.2025 15:11:00 EET | Press release

Regula, a global developer of identity verification solutions, has been recognized by customers on G2’s review platform as one of the fastest-rising and most trusted vendors in the identity verification market. Regula is named as a Leader in three G2 Winter 2026 Grid® Reports for Identity Verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218134153/en/ Regula is recognized as a Leader in G2’s Winter 2026 Grid Reports for Identity Verification, reflecting strong customer satisfaction and enterprise-grade IDV capabilities. This season, Regula earned a Leader placement in G2’s Overall Grid® for Identity Verification Software, reflecting strong customer satisfaction and a growing presence in the market. The company was also named a Leader in the Momentum Grid® Report for Identity Verification, highlighting accelerating demand for Regula’s solutions and increasingly positive feedback from users. In addition, Regula a

Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 15:00:00 EET | Press release

Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed Khan, Executive Vice President, Intelligent Systems, Aptiv. “Our collaboration with Vecna Robotics

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 15:00:00 EET | Press release

Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorders remain among the most debilitating and underserved conditions worldwide, with more than 20 million people affected and facing considerable disability, elevated relapse rates, and reduced life expectancy. Despite decades of need, current treatments often fall short in both efficacy and tolerability. Syremis’ lead program, ST-905, is a dual M1/M4 muscarinic agonist under development for schizophrenia and other neuropsychiatric conditions and is currently in Phase 1. The molecule’s differentiated potency

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye